SFTBY - Qualcomm-Apple Chip Supply Agreement Report On AstraZeneca CEO's Alleged Intention To Step Down Apple & Google Face Off in Antitrust Showdown: Today's Top Stories | Benzinga
Benzinga
Qualcomm Announces Chip Supply Agreement With Apple
- Qualcomm Inc (NASDAQ: QCOM) stock is trading higher Monday after the chip designer forged a deal with Apple Inc (NASDAQ: APPL).
- Under the deal, Qualcomm will supply Snapdragon 5G Modem?RF Systems for the iPhone maker's smartphone launch in 2024, 2025, and 2026.
- The agreement eyes a 20% share of chipset supply for smartphone launch in 2026.
Vietnam Airlines Eyes Monumental $10 Billion Deal With Boeing
- In a strategic move that could potentially reshape its fleet, Vietnam Airlines JSC is nearing a monumental deal with Boeing Co (NYSE: BA).
- The agreement involves the acquisition of about 50 Boeing 737 Max jets, a transaction estimated to be valued at a staggering $10 billion.
- The prospective deal not only signifies a massive win for Boeing but also marks a departure for Vietnam Airlines from its existing all-Airbus single-aisle jet fleet.
- The airline is reportedly looking to replace over 40 older-generation Airbus SE A321 planes with this new acquisition.
Welltower Raises FY23 FFO Outlook On Strong Capital Deployment & Senior Housing Business
- Welltower Inc (NYSE: WELL) raised its FY23 FFO outlook and provided a business update. The company increased FY23 normalized funds from operations (FFO) per share guidance to $3.51 – $3.60 from $3.48 - $3.59 earlier.
- The bullish stance reflects continued strength in the company's Seniors Housing Operating (SHO) portfolio and strong capital deployment activity.
- Also, WELL continues to see an increase in recognized renewal rates and improving street rates, accelerating RevPAR growth of 6.7% in FY23.
- Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has entered a development and commercialization agreement with Samsung Bioepis.
- The agreement provides Sandoz exclusive rights to commercialize the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland, and the U.K. Other specific terms of the agreement are confidential.